Exploring Strategies for Combating Weight Loss: Unveiling Safe and Sustainable Long-Term Treatment Approaches
ACPE Activity Number: 0204-0000-23-409-H01-P
Content Release Date: 12/18/2023
Expiration Date: 02/26/2025
Activity Type: Application-based
CE Credits: 1 contact hour (0.1 CEU)
Activity Fee: Free
Activity Overview
Obesity is a chronic disease complicated by the body’s drive to regain any lost weight. Short-term weight loss may be accomplished through dietary interventions, but hormones, nutrients, and peptides strive for homeostasis by counteracting weight loss. Early intervention with pharmacotherapy can counteract these mechanisms, allowing the patient to maintain their weight loss.
This educational activity will review mechanisms of weight loss and resistance as well as approaches to weight loss. Additionally, this activity will evaluate clinical studies and evidence of pharmacologic treatment options for obesity.
*Please note, this activity was presented live as a live webinar on 12/18/2023. You can only claim credit once for this activity; live or home study
More in this Series:
Podcasts: What You Need to Know About Obesity and Newer Treatments – Part 1
What You Need to Know About Obesity and Newer Treatments – Part 2
On-Demand Activity: Clinical Case Studies: Best Practices for the Use of Pharmacotherapy in Obesity
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Target Audience
This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, and ambulatory clinics who care for or are interested in the care of patients with obesity.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Discuss the mechanisms the body employs to fight weight loss and opportunities for safe and effective long-term treatment options beyond dietary and lifestyle interventions.
- Compare currently available treatments for obesity, including glucagon-like peptide 1 receptor agonists.
1. Introduction
2. Presentation
3. Q & A
Faculty
|
|
Jennifer N. Clements, PharmD, BCPS, BCACP, BC-ADM, CDCES, FCCP, FADCES, Activity Chair |
|
Dr. Clements is a clinical professor and director of Pharmacy Education with the University of South Carolina, College of Pharmacy at the School of Medicine – Greenville Campus. Dr. Clements earned her PharmD from Campbell University in 2006 and completed a primary care pharmacy practice residency in 2007 at the Ralph H. Johnson VA Medical Center in Charleston, South Carolina. She is a board-certified pharmacotherapy specialist, board-certified ambulatory care pharmacist, certified diabetes care and education specialist, and board certified in advanced diabetes management. Dr. Clements has authored numerous publications and presentations related to diabetes and obesity pharmacotherapy. |
|
 |
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP |
|
Dr. Isaacs is an endocrine clinical pharmacy specialist and the director of Education and Training in Diabetes Technology at the Cleveland Clinic. Dr. Isaacs serves in leadership roles for several pharmacy and diabetes organizations. She served on the ADA Professional Practice Committee for 2020-2023, the committee that updates the ADA Standards of Care. She is a national board member of the Association of Diabetes Care and Education Specialists. Dr. Isaacs was awarded the Ohio Pharmacists Association Under 40 Award in 2019 and was the 2020 ADCES Diabetes Care and Education Specialist of the Year. In 2022, she was inducted into the Southern Illinois University Edwardsville Hall of Fame for her far-reaching contributions in patient care. |
|
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Jennifer N. Clements: Novo Nordisk – Speaker’s bureau, Xeris Pharmaceuticals – Consultant, Embecta – Advisory board
- Diana Isaacs: Dexcom – Speaker’s bureau , Abbott – Speaker’s bureau, Novo Nordisk – Speaker’s bureau, Lilly - Speaker’s bureau, Sanofi – Consultant
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Methods and CE Requirements
This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
| Provided by ASHP Supported by an educational grant from Novo Nordisk Inc. |